Trump faces an ACA subsidy conundrum

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Generics of old GLP-1s could make new versions cheaper

Two of the oldest GLP-1 drugs have gone generic, and that could help Medicare bargain for lower prices on Ozempic and other brand-name versions of semaglutide, right as the public health insurance program considers covering them for weight loss.

It’s confusing to keep track of the developments related to GLP-1s and how generics could impact the price of the current blockbusters.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease – Biotech Investments

EQS-News: ActiTrexx GmbH / Key word(s): Study ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease 19.03.2024 / 10:00 CET/CEST The

March 20, 2024

New study links brain activity with daily behavior and long-term mental health

In a rare, longitudinal study, researchers from Aalto University and the University of Oulu tracked one person’s brain and behavioral activity for five months using

October 9, 2024

Novel tool holds great promise for studying mitochondrial calcium signaling

Mitochondrial calcium signaling is crucial for energy metabolism and calcium homeostasis, but monitoring it accurately is challenging due to pH fluctuations.

December 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.